OncoMatch/Clinical Trials/NCT06906341
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Is NCT06906341 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Relacorilant 150 mg once daily (QD) and Nab-paclitaxel 80 mg/m^2 for ovarian cancer.
Treatment: Relacorilant 150 mg once daily (QD) · Nab-paclitaxel 80 mg/m^2 · Bevacizumab 10 mg/kg — This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Ovarian Cancer
Endometrial Cancer
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: systemic anticancer therapy
1 to 3 lines of prior systemic anticancer therapy
Must have received: systemic anticancer therapy — endometrial cancer
1 to 2 lines of prior systemic anticancer therapy for endometrial cancer
Must have received: platinum-based chemotherapy — endometrial cancer
Prior treatment with a platinum agent
Must have received: anti-PD-L1 therapy — endometrial cancer
Prior treatment with an approved anti-Programmed Cell Death Ligand 1 (PD[L]1) antibody
Cannot have received: relacorilant
Prior enrollment in a clinical trial of relacorilant
Cannot have received: weekly paclitaxel or nab-paclitaxel (paclitaxel, nab-paclitaxel)
Has progressed while receiving weekly paclitaxel or nab-paclitaxel
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- 150 · Palo Alto, California
- 014 · San Francisco, California
- 544 · Fort Myers, Florida
- 543 · West Palm Beach, Florida
- 518 · Minneapolis, Minnesota
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06906341 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior relacorilant, weekly paclitaxel or nab-paclitaxel disqualifies patients from enrollment.
What disease stage is eligible?
Stage III or IV is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages